PLX Protalix BioTherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: PLX

Price (delayed)

$2.605

Market cap

$209.89M

P/E Ratio

10.85

Dividend/share

N/A

EPS

$0.24

Enterprise value

$190.96M

?
Relative Growth: Rel. Growth: 48
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 94
Relative Profitability: Rel. Profitability: 98

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies ...

Highlights
PLX's EPS has surged by 200% year-on-year and by 26% since the previous quarter
The gross profit has surged by 57% year-on-year and by 4.4% since the previous quarter
Protalix BioTherapeutics's quick ratio has decreased by 8% QoQ but it has increased by 3.4% YoY
PLX's debt has soared by 72% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protalix.com
Peers: NBIX PFE TEVA

Key stats

What are the main financial stats of PLX

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
0.58%
1 week
-0.19%
1 month
12.28%
1 year
62.81%
YTD
44.72%
QTD
11.8%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$80.62M
Gross profit
$55.79M
Operating income
$23.29M
Net income
$18.95M
Gross margin
69.2%
Net margin
23.5%
Protalix BioTherapeutics's operating income has surged by 183% YoY and by 18% QoQ
PLX's net margin has soared by 133% YoY and by 17% from the previous quarter
The operating margin has soared by 117% YoY and by 12% from the previous quarter
The gross profit has surged by 57% year-on-year and by 4.4% since the previous quarter

Price vs fundamentals

How does PLX's price correlate with its fundamentals

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
PLX P/E details
P/E
10.85
P/B
2.94
P/S
2.58
EV/EBIT
7.73
EV/EBITDA
7.27
EV/Sales
2.37
PLX's EPS has surged by 200% year-on-year and by 26% since the previous quarter
Protalix BioTherapeutics's equity has increased by 43% YoY and by 6% QoQ
PLX's price to sales (P/S) is 35% higher than its 5-year quarterly average of 1.9 and 2.8% higher than its last 4 quarters average of 2.5
Protalix BioTherapeutics's revenue has increased by 30% YoY and by 6% from the previous quarter

Efficiency

How efficient is Protalix BioTherapeutics business performance
The ROA has soared by 131% YoY and by 13% from the previous quarter
Protalix BioTherapeutics's return on equity has surged by 115% YoY and by 12% QoQ
PLX's return on sales has surged by 107% year-on-year and by 13% since the previous quarter
The return on invested capital has surged by 65% year-on-year and by 8% since the previous quarter

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 183% greater than its total liabilities
PLX's total assets is up by 41% year-on-year and by 8% since the previous quarter
The total liabilities has increased by 36% YoY and by 11% from the previous quarter
PLX's debt is 87% less than its equity
PLX's debt has soared by 72% YoY and by 9% from the previous quarter
Protalix BioTherapeutics's equity has increased by 43% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.